Voyager Therapeutics, Inc. VYGR
2.68
(0.12)
(4.29%)
as of 25 Sep
- Market cap
- $172.5M
- P/E
- 0.0×
Follow VYGR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(46.09%) | (48.29%) | (52.26%) | (54.09%) | |
| (35.50%) | (37.10%) | (40.74%) | (41.45%) | ||
ROIC |
(804.33%) | 0.00% | (247.40%) | (192.55%) | |
Return on Tangible Assets |
(64.23%) | (63.25%) | (82.29%) | (89.97%) | |
Average Days of Receivables |
47.05 | 17.29 | 16.45 | 33.41 | |
Free Cash Flow per Share |
(2.02) | (2.30) | (2.18) | (2.01) | |
Free Cash Flow |
(118.86) | (135.06) | (129.94) | (121.42) | |
Capital Expenditures |
(2.12) | (2.60) | (1.95) | (0.85) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(27.23%) | (33.75%) | (40.61%) | (44.54%) | |
Accounts Receivable Turnover |
2.64 | 19.73 | 19.44 | 12.14 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
428.87% | 333.57% | 350.06% | 343.77% | |
Selling, General and Administrative Expense of Revenue |
118.86% | 92.99% | 99.10% | 96.31% | |
Share Based Compensation of Revenue |
47.91% | 36.63% | 37.27% | 34.54% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 1.11 | 1.10 | 1.12 | |
Depreciation/Fixed assets |
0.01 | 0.08 | 0.13 | 0.18 | |
Capex/Depreciation |
(32.20) | (2.39) | (1.19) | (0.42) | |
Revenue per Share |
0.53 | 0.69 | 0.61 | 0.57 | |
Operating CF per Share |
(1.99) | (2.26) | (2.15) | (1.99) | |
Capex per Share |
(0.04) | (0.04) | (0.03) | (0.01) | |
Capex to Sales |
0.07 | 0.06 | 0.05 | 0.02 | |
Net Profit Margin |
(404.85%) | (296.53%) | (319.61%) | (312.63%) |
Columns are period end dates